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Abstract
Background
Human papillomavirus (HPV) vaccination and the implementation of primary HPV screening
in the Netherlands will lead to a lower cervical disease burden. For evaluation and further
improvement of prevention, it is important to estimate the magnitude and timing of health ben-
efits of current and alternative vaccination strategies such as vaccination of boys or adults.
Methods and findings
We evaluated the impact of the current girls-only vaccination program and alternative strate-
gies on cervical disease burden among the first four vaccinated five-year birth cohorts,
given the context of primary HPV screening. We integrated the existing microsimulation
models STDSIM (HPV transmission model) and MISCAN-Cervix (cervical cancer screening
model). Alternative vaccination strategies include: improved vaccination uptake, including
routine boys vaccination, and offering adult vaccination at sexual health clinics. Our models
show that the current vaccination program is estimated to reduce cervical cancers and can-
cer deaths by about 35% compared to primary HPV screening in the absence of vaccination.
The number needed to vaccinate (NNV) to gain 1 life year is 45. The most efficient alterna-
tive vaccination strategies are: 1) improving coverage of girls to 80% (NNV = 42); and 2) rou-
tine vaccination for girls and boys at 80% coverage (incremental NNV = 155), with cervical
cancer mortality reductions estimated at 50% and 60% respectively.
Conclusions
While the current program already substantially reduces cervical cancer incidence and mor-
tality, prevention can be further improved by increasing vaccination uptake and extending
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vaccination to boys. As not all cervical cancer deaths will be prevented, screening participa-
tion should still be encouraged.
Introduction
Cervical cancer is the fourth most common cancer among women worldwide [1], with the
human papillomavirus (HPV) as its necessary cause. Over the past years, several countries
have implemented vaccination against the most oncogenic types HPV-16 and HPV-18. While
clinical trials indicated that the currently licensed bivalent, quadrivalent, and nonavalent vac-
cines are highly effective against HPV-16 and HPV-18 infection [2–4], coverage levels in most
countries remain rather disappointingly low [5]. However, by reducing HPV prevalence in the
population, unvaccinated women are (indirectly) protected as well (i.e. herd immunity) [6, 7].
We recently estimated that HPV-16 and HPV-18 incidence in the Netherlands will substan-
tially decline by about 60% under continuation of the current girls-only vaccination program
[7]. Alternative vaccination strategies, such as efforts to increase vaccination coverage among
girls, the inclusion of boys, or vaccinating men at sexual health clinics, have also been explored
and in some countries even implemented [8, 9]. Finally, the cervical cancer screening program
in the Netherlands was renewed in 2017 by offering primary HPV screening instead of cytol-
ogy to women starting at age 30, and by offering fewer lifetime screens [10]. Given the context
of new screening strategies, it is important to evaluate the health benefits of current and alter-
native HPV vaccination strategies in order to support decision making on improving HPV
vaccination uptake and targeting.
Mathematical modeling has been used to estimate HPV incidences and the associated cervi-
cal disease burden following vaccination, as well as to determine the most cost-effective cervi-
cal cancer screening strategy in the post-vaccination era [11–23]. However, in order to
accurately estimate the impact of vaccination, including herd-immunity and the complexity of
cervical cancer disease development, a comprehensive modeling approach that combines a
sexual network model for accurately predicting vaccination effects on HPV transmission and a
detailed model of cervical disease natural history and screening is crucial. Most models used
did not simulate HPV transmission through a sexual network [11–20], and therefore cannot
properly capture herd immunity effects, or did not specifically capture the complexity of cervi-
cal cancer disease progression and screening [9].
We developed an HPV transmission and cervical cancer screening modeling framework by
integrating two established and comprehensive microsimulation models of HPV transmission
(STDSIM) and cervical cancer development (MISCAN-Cervix). With this new modeling
framework, we estimated the cervical disease burden for the first cohorts who have received
HPV vaccination under the new cervical cancer screening program, while taking both the
direct and indirect effects of HPV vaccination into account. In addition, we determined the
change in cervical cancer burden under various foreseeable extensions of the current girls-
only vaccination program.
Methods
STDSIM model
STDSIM is an established stochastic microsimulation model of the spread and control of sexu-
ally transmitted infections (STIs) [24–26]. The model simulates the life course of individuals in
a dynamic heterosexual network, in which STIs such as HPV can spread. Each individual has
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its own characteristics that are either constant (e.g. date of birth and sex) or subject to change
(e.g., number of sexual partners, infection status). Events are determined by probability distri-
butions, and can lead to new events (e.g. birth leads to a future event of becoming sexually
active) or a cancellation of future events (e.g. death cancels all scheduled events concerning
sexual activity or STI transmission). More detailed information on the model can be found in
Hontelez et al.[25].
We have previously quantified STDSIM to the Netherlands to model the spread of HPV-16
and HPV-18. Briefly, we reproduced the Dutch population and its sexual network, based on
demographic and sexual data. As an independent validation of the underlying sexual network,
we simulated the transmission of chlamydia to validate the level of sexual risk behavior. The
model was able to closely reproduce the observed chlamydia prevalence levels, reassuring us
that the simulated sexual network is representative for the Dutch situation. We then intro-
duced HPV-16 and HPV-18 in the population to estimate the transmission probabilities and
acquired immunity dynamics necessary to reproduce the age-specific patterns in HPV-16 and
HPV-18 prevalence. All details on the model structure, the parameter quantification, and
model validation and underlying data for the Dutch setting, are described in detail by Mat-
thijsse et al. [26]
MISCAN-Cervix model
MISCAN-Cervix simulates the individual life histories of a population of women, based on
Dutch demographic and hysterectomy data. Women can acquire a high-risk HPV infection
that either clears naturally or leads to the development of pre-invasive cervical lesions. These
lesions regress or develop into invasive cervical cancer. Death can follow from cervical cancer
or from other causes. Multiple infections can occur at the same time, which are independent
of each other. Interventions such as hysterectomy and screening can affect these life histories.
Pre-invasive stages and FIGO (International Federation of Gynecology and Obstetrics) 1A
cases can only be detected by screening, since they are assumed to be asymptomatic, whereas
FIGO 1B or worse can also be clinically diagnosed [27].
The model divides cervical disease into seven sequential stages: high-risk HPV infection,
three pre-invasive stages (cervical intraepithelial neoplasia (CIN) grade 1, 2, and 3), and three
invasive stages (FIGO stages 1A, 1B, and 2 or worse; S2 Fig). Age-specific onset parameters set
the probability of women to acquire an HPV infection and develop lesions or cancer. In the
model, most HPV infections are transient. Lesions in pre-invasive stages can also regress.
While CIN 1 and CIN 2 can develop without an HPV infection (in which case they will always
regress in our model), CIN 3 and cervical cancer can only develop in the presence of a high-
risk HPV infection. More information can be found in S1 Text, De Kok et al. [28], Van Rosma-
len et al. [29], and Naber et al. [27].
Integrated modeling framework
Using STDSIM, we estimated the relative reduction in incidence of HPV-16 and HPV-18 for a
specific vaccination strategy over time and for different cohorts, compared to no vaccination.
To determine the effect of vaccination on cervical precancerous lesions and cancer, we subse-
quently used these estimates from the STDSIM model as input for the MISCAN-Cervix
model.
In previous studies with the MISCAN-Cervix model, an aggregate probability to acquire an
HPV infection and develop a lesion or cancer was defined for all high-risk HPV types [25, 27,
28]. For the purpose of this study, we divided them into separate probabilities for HPV-16,
HPV-18, and the other high-risk types to reproduce the observed attributable proportions of
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HPV-16 and HPV-18 in high-risk HPV prevalence, lesions and cervical cancer, while we
maintaining the original aggregate values of these probabilities. The observed attributable pro-
portions of HPV-16 in CIN 1, CIN 2, CIN 3, and invasive cervical cancer are 15.4%, 37.6%,
47.2%, and 62.5%, respectively, after correcting for co-infections with multiple types (S8
Table) [27, 30]; and 7.8%, 7.4%, 4.7%, 17.2% for HPV 18, respectively. Of the transient high-
risk HPV infections, 25.4% is attributable to HPV-16 and 8.2% to HPV-18 [31]. In an unvacci-
nated population, the estimated proportion of HPV-16 and HPV-18 in transient high-risk
HPV infections, precancerous lesions, and invasive cervical cancers in MISCAN-Cervix corre-
spond well with the observed proportions, except for an underestimation of CIN 2 attributable
to HPV-16 and a slight overestimation in CIN 1 and CIN 3 attributable to HPV-18 (S8 Table).
With the integrated modeling framework we simulated a population of 10 million women
divided over four birth cohorts in MISCAN-Cervix with the following birth years: 1993–1997,
1998–2002, 2003–2007, and 2008–2012. These birth cohorts were chosen because they are the
first vaccinated cohorts in the Netherlands. The trends in relative reductions in age-specific
incidence of HPV-16 and HPV-18 from STDSIM per birth cohort, which incorporates both
the direct and indirect effects of vaccination, were then applied to the age-specific onset
parameters in the MISCAN-Cervix model (S4 Fig).
Vaccination strategies
We used largely the same assumptions to model the impact of HPV vaccination as in our pre-
vious studies [7, 9]. Briefly, we modeled the current vaccination strategy and observed vaccina-
tion uptake in the Netherlands: i.e. a catch-up campaign for girls aged 13–16 years in 2009
(coverage of 50%), and annual vaccination of girls aged 12 years (coverage of 60%). Vaccine
efficacy is set at 94.7% for HPV-16 and at 92.3% for HPV-18 [3, 32]. We assumed vaccine effi-
cacy to be independent of HPV status at the time of vaccination, as vaccination still has a sub-
stantial protective effect in women previously exposed to HPV-16 and HPV-18 [33, 34].
Infection clearance is not accelerated by the vaccine in our model.
The alternative vaccination strategies represent foreseeable changes of the current girls-
only program in various ways from 2017 onwards. First, we increased routine vaccination cov-
erage among girls up to 80% and 100%, as the familiarity of the vaccine has increased and
more girls might be inclined to get vaccinated in the future. Second, we included routine vacci-
nation for boys, assuming the same target age groups and uptake as for girls (i.e. 60%, 80%,
and 100% coverage). However, as bivalent vaccine efficacy estimates for boys are unavailable,
efficacy for boys was assumed to be equal to the quadrivalent vaccine efficacy for boys (78.7%
for HPV-16; 96.0% for HPV-18) [35]. Finally, we included adult vaccination at sexual health
clinics for women and for both men and women aged 15–29 years. For the adult vaccination
strategies, we assumed an efficacy of 77.4% against both HPV-types for women older than 24
years [34]. For men older than 24 years, vaccine efficacy was assumed to be 64.5% for HPV-16
and 80.6% for HPV-18 [9, 34]. In the last strategy, where the vaccine is offered to both sexes
during STI consultations, routine vaccination for boys is included as well.
Cervical cancer screening
We subsequently simulated the new cervical cancer screening program, in which primary
HPV screening with reflex cytology and cytology triage after 6 months will be offered to
women aged 30, 35, 40, 50, and 60 years. Additional HPV testing will be offered at age 45 and
55 for women who either have a positive HPV test or do not attend screening at ages 40 and
50, respectively. Women who attended screening at age 60 and tested positive for HPV will
also be invited at age 65. We assumed that 10% of the population never attends screening and
Health impact of HPV vaccination with primary HPV screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0202924 September 4, 2018 4 / 15
has a higher background risk than the 90% potential attenders [29]. Attendance among the
potentially attending women for primary testing and compliance with colposcopy referrals
and triage testing is based on the current screening program (see also S9 Table), and is inde-
pendent of vaccination status in our model [36]. In the new screening program, a self-sam-
pling kit is offered to women who do not attend screening at the general practitioner. Go¨k
et al. estimated that the effect of mailing self-sampling kits to all non-attendees of the Dutch
cervical cancer screening program would generate an extra 5.2% attendance [37]. Since the
self-sampling kit will be offered using opt-in (instead of opt-out as in the PROHTECT trial),
we assumed that 3% of the non-attenders would opt-in for the self-sampling kit [38].
We used the same specificity and sensitivity of cytology for detecting precancerous lesions
and invasive cancer for testing at least atypical squamous cells of undetermined significance
(ASC-US) as in our previous study, i.e. a sensitivity of 40% for CIN 1, 50% or CIN 2, and 75%
for CIN 3 and cervical cancer, and a specificity of 98% [27, 39]. For the HPV test, we assumed
a 94% sensitivity for detecting high-risk HPV infections, regardless of whether a CIN lesion or
cancer was also present (although a woman with cancer is always infected with HPV) [26, 29].
In our model, CIN treatment leads to full recovery. Subsequently, women can acquire new
HPV infections and develop CIN lesions and/or invasive cancer. For invasive cancer, survival
probabilities depend on the woman’s age and cancer stage (FIGO 1B or FIGO 2+) at diagnosis,
based on data from the Dutch Cancer Registry [40]. After receiving treatment for cancer,
women are no longer at risk for HPV or cervical disease. The survival probabilities by age and
stage can be found in Naber et al.[27].
Model outcomes
STDSIM provides us with the estimated age-specific HPV-16 and HPV-18 incidence and vac-
cinated individuals over time. MISCAN-Cervix determines the most severe state of each
woman (i.e. from least to most severe: normal, HPV infected, CIN 1, CIN 2, CIN 3, FIGO 1A,
FIGO 1B, and FIGO 2+) and the number of life years spent in each state (see also S1 Text). For
the current study, the main outcomes are the relative reductions in HPV-16 and HPV-18 inci-
dence over time, and the numbers of diagnosed CIN 1, CIN 2, CIN 3 and cervical cancer, and
cancer-related deaths. We also estimated the (incremental) number needed to vaccinate
(NNV) to gain one life year, in order to determine the most efficient vaccination strategies.
Sensitivity analyses
Huijsmans et al. [41] recently showed that HPV prevalence in screening eligible women in the
Netherlands could be twice as high compared to the earlier data our model fit was based upon
[42]. Therefore, we re-analyzed the impact of the current vaccination program in the models
with doubled HPV prevalence prior to the implementation of vaccination in the sensitivity
analyses. The overall prevalence among women was doubled by increasing sexual risk behavior
in STDSIM as well as by doubling the onsets of transient infections in MISCAN. Also, we var-
ied the attendance of the screening program by assuming a 20% higher and lower attendance
(S9 Table), as we cannot be sure that screening attendance of the new program will be the
same as of the current program.
Results
Fig 1 shows the estimated relative reductions in the incidence of HPV-16, HPV-18, cervical
cancer, and diagnosed CIN per birth cohort under the current vaccination program compared
to no vaccination. For all cohorts, the relative incidence reductions were larger for HPV-16
than HPV-18 infections. The younger the birth cohort, the larger the health impact of HPV
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vaccination. The larger reductions in HPV incidence and corresponding age patterns for
younger cohorts are attributable to higher levels of herd immunity, as HPV transmission
reduces over time. Also, almost all girls in cohort 1 have been offered HPV vaccination by
means of the catch-up campaign given their age, which had a lower coverage rate than the
annual vaccination of 12-year-old girls (i.e. 50% compared to 60%). Cohort 1 therefore has rel-
atively fewer vaccinated girls than the younger cohorts, as the younger cohorts all received vac-
cination according to the annual vaccination of 12-year-old girls. While for the younger
cohorts a trend by age is visible (ranging from over 50% in cervical cancer incidence for
women younger than 25 years to almost 40% for women aged 65+), the reductions for the old-
est cohort (cohort 1) are quite stable over all ages (between 22% and 25% reduction over all
ages). A slight increase in the reduction of CIN lesions is visible at the last screening age. As
the percentage of CIN attributable to HPV-16 and HPV-18 slightly increase with age in the
model, the impact of the vaccine on CIN is larger at these ages.
Our models predict that the HPV-16 and HPV-18 incidence reductions will lead to a 35%
lifetime reduction in clinically detected cancers and cervical cancer deaths, and almost 40% in
Fig 1. Relative reductions by age group in the incidence of HPV-16 (A), HPV-18 (B), cervical cancer (C), and CIN (D) for the first four successive 5-year birth
cohorts (vaccinated and unvaccinated women) that underwent the current girls-only vaccination program, compared to no vaccination. Cohort 1 is born between
1993–1997; cohort 2 between 1998–2002; cohort 3 between 2003–2007; and cohort 4 between 2008–2012. The ages in parentheses on the x-axis of Fig 1D depict the
additional screen ages 45 and 55 if women did not attend screening or tested HPV positive at ages 40 and 50, respectively, and at age 65 if women attended and tested
positive at age 60.
https://doi.org/10.1371/journal.pone.0202924.g001
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screen-detected cancers, compared to no vaccination (Table 1). Somewhat larger health gains
are accomplished when coverage of HPV vaccination among girls increases to 80% and 100%,
i.e. 43% reduction in cervical cancer cases and cancer deaths under 80% coverage, and over
50% reduction in cancer cases and deaths under full coverage. However, even when vaccine
uptake among girls can be increased from 60% to 80%, the health gains are still lower as com-
pared to expanding the target group to males. Including males by offering adult vaccination at
STI clinics for both sexes (which also incorporates routine boys vaccination) and solely includ-
ing routine boys vaccination with current uptake levels are predicted to reduce the number of
cervical cancer deaths by 49% and 45%, respectively, as compared to 43% when coverage
among girls is increased to 80%. Including boys with increased uptake of 80% for both sexes
leads to larger reductions in cervical cancer cases (54%) and deaths (56%) than full coverage
among girls (51% and 52%, respectively). As expected, the largest health gains are accom-
plished when full coverage can be achieved for routine girls and boys vaccination, with reduc-
tions of 61% and 64% in cancer cases and deaths, respectively.
Under the current vaccination program, vaccinating 45 girls (NNV = 51,070/1,134) will
save one life year by preventing cervical cancer death, when compared to no vaccination (Fig
2). Most efficient strategies are: achieving full coverage among girls (NNV = 42); and achieving
full coverage of routine vaccination for both sexes (incremental NNV = 155). Less efficient are
routine vaccination for both sexes with 60% and 80% coverage, and vaccination during STI
consultations for both sexes. When the strategies with full coverage are excluded from the anal-
yses, improving coverage to 80% in girls and both sexes become the most efficient strategies.
The sensitivity analyses in Table 2 show that, while the absolute disease burdens with and
without vaccination differ, the relative health impact of the current vaccination program is
nearly similar under alternative levels of cervical cancer screening attendance and with a
Table 1. Health impact of the current girls-only vaccination program and alternative vaccination strategies on cervical disease per 100,000 women. The relative life-
time change as compared to no vaccination are shown between parentheses. In the alternative vaccination strategies, boys, and adult women and men are included in the
vaccination strategies in addition to girls. Vaccination at STI consultations for adult males and females also includes routine vaccination for boys.
Strategy False-positive
referrals
CIN 1 CIN 2 CIN 3 Clinically detected
cases
Screen-detected
cancers
Cervical cancer
deaths
Life years
lost
No vaccination 543 2,473 1,655 2,413 444 136 193 3,089
Current program (60%
cov.)
458 (-16%) 2,121
(-14%)
1,361
(-18%)
1,778
(-26%)
289 (-35%) 83 (-39%) 126 (-34%) 1,979
(-36%)
Improved coverage among girls
Girls (80% cov.) 448 (-17%) 2,061
(-17%)
1,318
(-20%)
1,696
(-30%)
256 (-42%) 76 (-44%) 110 (-43%) 1,772
(-43%)
Girls (100% cov.) 431 (-21%) 2,006
(-19%)
1,276
(-23%)
1,619
(-33%)
215 (-52%) 70 (-49%) 92 (-52%) 1,555
(-50%)
Inclusion of also boys and adults
Boys (60% cov.) 443 (-18%) 2,037
(-18%)
1,310
(-21%)
1,682
(-30%)
246 (-45%) 74 (-46%) 105 (-45%) 1,715
(-44%)
Boys (80% cov.) 430 (-21%) 1,976
(-20%)
1,258
(-24%)
1,596
(-34%)
201 (-55%) 67 (-51%) 85 (-56%) 1,469
(-52%)
Boys (100% cov.) 416 (-23%) 1,922
(-22%)
1,222
(-26%)
1,526
(-37%)
168 (-62%) 60 (-56%) 70 (-64%) 1,285
(-58%)
STI consultations (F) 454 (-16%) 2,093
(-15%)
1,336
(-19%)
1,732
(-28%)
274 (-38%) 80 (-42%) 119 (-38%) 1,885
(-39%)
STI consultations (F
+M)
438 (-19%) 2,004
(-19%)
1,286
(-22%)
1,631
(-32%)
231 (-48%) 70 (-49%) 98 (-49%) 1,621
(-48%)
CIN = cervical intraepithelial neoplasia; cov. = coverage; STI = sexually transmitted infections; F = females; M = males
https://doi.org/10.1371/journal.pone.0202924.t001
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higher baseline HPV prevalence. The largest difference in health impact between the base case
and sensitivity analyses was found when we assumed a higher baseline HPV prevalence, and
there was only a 3 percentage points difference in the relative reduction in cervical cancer
deaths and life years lost.
Discussion
Using a comprehensive modeling framework, linking the established STDSIM and MISCAN--
Cervix models, we have estimated the health impact of the current girls-only vaccination pro-
gram and various alternative vaccination strategies under the new cervical cancer screening
program in the Netherlands. HPV-16 and HPV-18 incidence reductions achieved under the
current girls-only vaccination are predicted to lead to substantial reductions in cervical disease
burden, with an estimated reduction of 35% in clinically detected cancers and cervical cancer
deaths, and almost 40% in screen-detected cancers, compared to no vaccination. The NNV of
the current girls-only program is 45. Largest health gains will be accomplished when full cover-
age can be achieved for routine vaccination of both girls and boys. For this strategy, the incre-
mental NNV to gain one life year is 155, compared to the most efficient strategy of full
coverage among girls (NNV = 42).
The larger reductions in HPV incidence and corresponding age patterns for younger
cohorts are attributable to higher levels of herd immunity. This was also demonstrated in the
Fig 2. Estimated number of life years gained and corresponding number of vaccinated individuals for the current vaccination program and alternative strategies
as compared to no vaccination program. The current vaccination program has been implemented in 2009. The alternative vaccination strategies commence from 2017
onward, in addition to the current program. Numbers are scaled to a population of 100,000 women in 2017. Cov. = coverage; STI = sexually transmitted infection.
https://doi.org/10.1371/journal.pone.0202924.g002
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study of Bogaards et al., in which they concluded that the reduction of hazard in unvaccinated
women increases with birth cohort year [43]. For even younger cohorts than the ones included
in our study, the HPV incidence reductions will be more substantial than in the youngest sim-
ulated birth cohort, and will therefore have more health gains due to vaccination.
We have estimated the reduction in cervical cancer due to HPV vaccination before, but in a
crude way [7]. In the current study, the estimated reduction in (screen- and clinically detected)
cancers is smaller than the incidence reduction we found in our earlier study under the current
vaccination program (36% versus 48%, respectively). Three distinctions between the studies
are important to consider when interpreting this difference. First, in the previous study we
used a relatively simple calculation for the reduction in cancers instead of a detailed microsi-
mulation model. Second, primary screening methods differ between both studies. While the
previous study uses incidence data from a population with primary cytology screening, we
simulated here the new program with primary HPV screening, which is expected to prevent
more cervical cancer cases itself [10]. Third, in the previous study, we used the incidence
reduction when a steady state is achieved (approximately 70 years following the introduction
of HPV vaccination), while here we estimated the lifetime health impact of the four earliest
vaccinated cohorts. As the impact of HPV vaccination on HPV incidence has not reached its
full potential prior to the steady state, the cancer incidence reductions are smaller than for
younger, i.e. steady state, birth cohorts.
Including also routine vaccination for boys with 80% coverage was predicted to prevent
more deaths than reaching full coverage among girls (56% reduction versus 53%). However,
including boys appears less efficient, due to a larger increase in number of vaccinations
needed. We appreciate that full coverage of the vaccination program, either for only girls or
both sexes, might be unrealistic. We therefore also explored the efficiency of the vaccination
strategies when excluding the scenarios of full coverage (Fig 2). In that situation the most effi-
cient strategies include increasing coverage to 80% for girls (NNV = 43) and for both sexes
Table 2. Health impact of the current girls-only vaccination program under alternative levels of cervical cancer screening attendance and with doubled baseline
HPV prevalence. Results are shown per 100,000 women. The relative change as compared to no vaccination are shown between parentheses. Alternative levels of atten-
dance include either 20% higher or lower than the observed attendance in the current screening program.
False-positive
referrals
CIN 1 CIN 2 CIN 3 Clinically detected
cases
Screen-detected
cancers
Cervical cancer
deaths
Life years
lost
Base case
No vaccination 543 2,473 1,655 2,413 444 136 193 3,089
Current
program
458 (-16%) 2,121
(-14%)
1,361
(-18%)
1778
(-26%)
289 (-35%) 83 (-39%) 126 (-34%) 1,979 (-36%)
Higher attendance
No vaccination 637 2,836 1,896 2,647 389 121 174 2,542
Current
program
531 (-17%) 2,438
(-14%)
1,556
(-18%)
1,961
(-26%)
256 (-34%) 72 (-40%) 115 (-34%) 1,619 (-36%)
Lower attendance
No vaccination 451 2,059 1,371 2,097 566 144 240 4,222
Current
program
379 (-16%) 1,765
(-14%)
1,129
(-18%)
1,536
(-27%)
362 (-36%) 88 (-39%) 156 (-35%) 2,666 (-37%)
Higher baseline HPV prevalence
No vaccination 950 2,528 1,679 2,423 446 137 195 3,185
Current
program
808 (-15%) 2,172
(-14%)
1,375
(-18%)
1,786
(-26%)
285 (-36%) 82 (-40%) 123 (-37%) 1,950 (-39%)
CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; vacc. = vaccination
https://doi.org/10.1371/journal.pone.0202924.t002
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(incremental NNV = 115). These results indicate that including boys is an efficient strategy to
further improve cervical disease prevention, and that the higher the uptake, the more efficient
this strategy will be. Finally, our model shows that vaccination offered at STI consultations is
least efficient, likely due to the fact that people attending STI consultations have already been
exposed to HPV, and are more likely to either be infected with HPV, or be immune due to
clearance of an earlier infection, at the moment of vaccination.
Even though the models are quantified to data from the Netherlands, these results are gen-
eralizable to developed settings with a higher prevalence of HPV or cervical disease. While a
higher prevalence of HPV-related cervical disease would lead to a higher absolute number of
referrals and treatments, the relative reductions due to vaccination will not change substan-
tially, as long as the proportion of cervical disease attributable to HPV-16 and -18 remains the
same. This is supported by the sensitivity analysis with the higher HPV baseline prevalence (by
increasing the prevalence of transient infections), in which indeed absolute numbers differ
from those in the base case analysis, yet the relative reductions due to vaccination are similar.
Our study has four limitations that are noteworthy. First, in our model, we underestimated
the proportion of CIN 2 attributable to HPV-16, and slightly overestimated the proportion of
CIN 1 and CIN 3 attributable to HPV-18, compared to the observed proportions [30]. These
discrepancies are small though, and less relevant than the associated cancer cases and deaths,
which were estimated well. Also, they apply to all strategies, so that the comparative effects of
different scenarios are still of value. Second, it is still uncertain if the attendance rate of the
screening program will be influenced by the switch to primary HPV screening and the opt-in
procedure of the self-sampling kit. However, our sensitivity analyses showed that alternative
attendance rates do not influence the health impact estimates substantially. Third, our esti-
mates of the health impact are conservative, as we did not take cross-protection of the bivalent
vaccine or additional protective effects of the nonavalent vaccine into account. Finally, we
compared vaccination strategies based on the NNV to gain one life year, while policy decisions
are usually based on costs per life year gained. The NNV measure, however, is easy to interpret
and does allow for comparing vaccination strategies in terms of their efficiency to achieve the
main goal of HPV vaccination programs (i.e. reduce cervical cancer mortality). In a full cost-
effectiveness analysis, one would not only need to include the costs and benefits of HPV vacci-
nation and cervical cancer screening and treatment, but also those related to all other HPV-
related diseases, including e.g. also genital warts. This was beyond the scope of the current
work, but would be an interesting topic for further research.
We conclude that, already for the first vaccinated birth cohorts, the current vaccination pro-
gram will lead to substantial reductions in cervical cancer incidence and mortality in the Nether-
lands. Efficient strategies to further improve health gains are to increase vaccination uptake
among girls, or to extend the target group to routine boys vaccination with increased vaccination
uptake. As vaccination will not prevent all cervical cancer deaths, screening does not become
obsolete and participation should continue to be encouraged in the post-vaccination era.
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